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Abstract
Introduction—There is converging evidence supporting hyperactivity of the Hypothalamic-
Pituitary-Adrenal (HPA) axis in schizophrenia spectrum disorders (SSD), such as schizotypal
personality disorder (SPD), first-episode schizophrenia (FESZ) and chronic schizophrenia
(CHSZ). Such an aberrant HPA activity might have volumetric consequences on the pituitary
gland. However, previous magnetic resonance imaging (MRI) studies assessing pituitary volume
(PV) in SSD are conflicting. The main objective of this study was to examine further PV in SSD.
Methods—PV were manually traced on structural MRIs in 137 subjects, including subjects with
SPD (n=40), FESZ (n=15), CHSZ (n=15), and HC (n=67). We used an ANCOVA to test PV
between groups and gender while controlling for inter-subject variability in age, years of
education, socioeconomic status, and whole brain volume.
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Results—Overall, women had larger PV than men, and within the male sample all SSD subjects
had smaller PV than HC, statistically significant only for the SPD group. In addition, dose of
medication, illness duration and age of onset were not associated with PV.
Conclusion—Chronic untreated HPA hyperactivity might account for smaller PV in SPD
subjects, whereas the absence of PV changes in FESZ and CHSZ patients might be related to the
normalizing effects of antipsychotics on PV. SPD studies offer a way to examine HPA related
alterations in SSD without the potential confounds of medication effects.
Keywords
schizophrenia; first-episode; schizotypal; pituitary volume; MRI
1 INTRODUCTION
There is increasing evidence that suggests hyperactivity of the Hypothalamic-Pituitary-
Adrenal (HPA) axis in schizophrenia spectrum disorders (SSD). More specifically, the HPA
axis has been associated with stress responsivity, and there is also evidence that these two
systems are closely related in schizophrenia (Kaneko et al., 1992; Walker and Diforio,
1997). Of note, schizotypal personality disorder (SPD) is genetically related to
schizophrenia (Kendler et al., 1993), and shares clinical and biological features (Siever and
Davis, 2004). Some studies have investigated HPA axis functioning in SPD, which might
share HPA axis functioning with schizophrenia; SPD subjects might be better buffered
against dopaminergic and HPA over activation in response to stress (Mitropoulou et al.,
2004).
The HPA axis governs the release of cortisol, which enters the brain to coordinate
components of the stress system and to control the excitability of neuronal networks (de
Kloet et al., 1999). In response to stressors, corticotrophin-releasing hormone is released
from the paraventricular nucleus of the hypothalamus. This triggers the secretion of
adenocorticotropic hormone from the pituitary, which, in turn, leads to the secretion of
glucocorticoids from the adrenal glands, in particular cortisol (Walker et al., 2008). Cortisol
has an effect on brain function through specific receptors. That is, both fast and slow effects
occur as a result of activating these receptors. Modulation of HPA activity is a crucial
mechanism that enables the organism to meet changing demands of the environment. For
example, animal studies have shown that, at heightened levels, GCs can induce regression of
dendritic processes, inhibit neurogenesis, decrease neuronal survival following insults
(Sapolsky, 2003), and contribute to neuronal death in brain areas like the hippocampus, that
might be responsible for the volumetric changes reported in this area (Dickey et al., 2007).
HPA dysfunction in SSD has also been hypothesized to affect pituitary volumes. For
example, Pariante et al. (Pariante et al., 2004) reported increased pituitary volume (PV) in
medicated and neuroleptic-naïve patients with first episode psychosis, while smaller
volumes where found in patients with schizophrenia. Upadhyaya et al. (Upadhyaya et al.,
2007) studied PV in neuroleptic-naïve schizophrenia patients and found smaller volumes in
patients compared to healthy individuals. In contrast, MacMaster et al. (MacMaster et al.,
2007a) found increased volume after a 12 month follow up in patients with schizophrenia.
Tournikioti et al. (Tournikioti et al., 2007), on the other hand, reported no volumetric
difference between patients with chronic schizophrenia (CHSZ) and healthy controls. More
recently, Takahashi et al. (Takahashi et al., 2009) reported that PVs were larger in treated
SPD and schizophrenia than they were in a group of healthy controls.
As described, magnetic resonance imaging (MRI) studies assessing PV in schizophrenia
spectrum disorders are limited and conflicting. The main objective of this study was to
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examine further pituitary gland volume in subjects diagnosed with SPD, FESZ, CHSZ, and
healthy controls.
2 MATERIALS and METHODS
2.1 Subjects
One hundred and thirty seven subjects participated in this study, of which 70 were meeting
DSM criteria for a schizophrenia spectrum disorder (SSD; mean age±SD = 30±10 years,
71% male) and 67 were healthy controls (HC; mean age±SD = 30±10 years; 73% male).
Within the schizophrenia spectrum, 40 subjects were diagnosed with schizotypal personality
disorder (SPD; mean age±SD = 29±8 years; 50% male), 15 with first-episode schizophrenia
(FESZ; mean age±SD = 22±3 years; 100% male), and 15 with chronic schizophrenia
(CHSZ; mean age±SD = 41±9 years; 100% male). All subjects were right handed. The
project was approved by local institutional review boards at Harvard Medical School and at
the VA Boston Healthcare System. Following a full description of the study to the
participants, written informed consent was obtained.
All subjects were recruited and diagnosed as described in detail in previous studies
(Anderson et al., 2002; Dickey et al., 1999; Dickey et al., 2007; Dickey et al., 2000;
Hirayasu et al., 1998; Hirayasu et al., 2000b; Hirayasu et al., 2001; Kasai et al., 2003; Lee et
al., 2002; Shenton et al., 1992). Briefly, SPD subjects were a community-based sample
recruited at the VA Boston Healthcare System, Jamaica Plain Division, from newspaper
advertisements in the local community. Patients with FESZ were recruited from inpatient
units at McLean Hospital, and patients with CHSZ were recruited from the VA Boston
Healthcare System, Brockton Division. Patients and SPD subjects were diagnosed based on
the DSM III-R or DSM-IV criteria, using information from the Structured Clinical Interview
for DSM-III-R, by trained interviewers. Consistent with the literature (Hirayasu et al.,
2000a; Hirayasu et al., 1998; Hirayasu et al., 2001; Shenton et al., 1992) first episode was
operationally defined as the first psychiatric hospitalization (DeLisi et al., 1991; DeLisi et
al., 1997; Lieberman et al., 2001).
Healthy control subjects were recruited through newspaper advertisements in the community
and no control subject had an Axis I or II psychiatric disorder or a first-degree relative with
an Axis I psychiatric disorder with screening using the Structured Clinical Interview for
DSM-III-R Non-Patient Edition (SCID-NP).
All participants met criteria for age (18–55 years), IQ above 75, a normal brain MRI as
evaluated by a clinical neuroradiologist and a history negative for the following: seizures,
head trauma with loss of consciousness, neurologic disorder, and any lifetime history of
substance dependence.
2.2 MRI procedures
Participants were scanned at two locations (SPD and CHSZ at Brigham and Women’s
Hospital, Boston, MA; FESZ at McLean Hospital, Belmont, MA; HC at both locations). All
MR images were acquired on 1.5 Tesla General Electric Scanners (GE Medical Systems,
Milwaukee, Wisconsin). As mentioned in PNL’s Technical Report, geometrically
complicated ROI’s have no more inter-scan variation with the same rater than the intra-rater
reliability on the same scan. (http://pnl.bwh.harvard.edu/pub/papers_html/
TechnicalReport501.html) There were two MRI sequences that have been described in detail
previously (Dickey et al., 1999; Dickey et al., 2000). Briefly, the first sequence was a
coronal series of contiguous spoiled gradient-recalled acquisition (SPGR) images
(TR=35msec, TE=5msec, flip angle=45°, FOV=24cm, and matrix size=256x256x124, voxel
(volume of the pixel) dimensions=0.9375x0.9375x1.5 mm). The second acquisition was an
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axial series of contiguous double-echo (proton density and T2-weighted) images
(TR=3000msec, TE=30 and 80 msec, FOV=24cm, and an interleaved acquisition with 3.0-
mm slice thickness).
Scans were transferred to workstations for further image processing at the Psychiatry
Neuroimaging Laboratory (Brigham and Women’s Hospital, Boston, MA; http://
pnl.harvard.edu). First, the T2 scan was registered to the SPGR followed by an expectation-
maximization (EM) technique (Bouix et al., 2007; Pohl et al., 2007) used to segment the
brain into its major tissue classes: gray matter, white matter and cerebral spinal fluid. These
tissue classes were merged into a single label map to measure the subject’s whole brain
volume. The mask was checked by overlaying it onto the coregistered T2-scan to ensure that
all extracranial and skull structures were removed and all intracranial structures fully
preserved. The SPGR was then realigned using the line between the anterior and posterior
commissures and the sagital sulcus to correct for head tilt, and then re-sampled into isotropic
voxels of 0.9375mm3. The pituitary was traced on realigned and re-sampled SPGR images
using 3DSlicer (Surgical Planning Laboratory, Brigham and Women’s Hospital, Boston,
MA; http://www.slicer.org).
2.3 Tracing methods
One rater (FR) blind to subjects’ diagnoses, manually traced pituitary volumes on structural
T1 sequence MRIs for all study subjects. On a random subset of 10 cases, high intra-rater
(intraclass correlation coefficient r=0.81, p=0.01) and inter-rater reliability (FR and WSH;
intraclass correlation coefficient r=0.97, p<0.001) were observed.
The tracing method was adapted from previously published studies (Pariante et al., 2004;
Sassi et al., 2001; Upadhyaya et al., 2007). Briefly, each pituitary was first identified on the
sagital plane where an anterior and posterior border was marked and used to define the
number of coronal slices containing the pituitary. Then, the pituitary gland was traced in all
coronal slices where it could be visualized following well-defined anatomical boundaries,
i.e., the diaphragma sellae (superiorly), the sphenoid sinus (inferiorly), and the cavernous
sinuses (bilaterally). Bright voxels corresponding to the posterior pituitary were included, as
they are thought to be a reflection of vasopressin concentration (Fujisawa et al., 1987). The
pituitary stalk was excluded (Figure 1).
2.4 Statistical analyses
Sociodemographic and clinical differences between groups were assessed by one-way
analyses of variance (ANOVA), student t-test, or chi-square test. PV was analyzed using
univariate analysis of covariance (ANCOVA). Four ANCOVA models were sequentially
used. In the first model, all subjects were included. In the second model, females were
excluded because there were no females in the FESZ and CHSZ group. In the third model, a
model without CHSZ (and without females) was tested given the significant differences in
sample characteristics (as described below in the results section) between CHSZ and the
other groups, in particular age. Finally, in the fourth model, we directly compared PV
between the SPD and HC sample given their similarities in sample characteristics, and to
study further group and gender effects. Model covariates were used because they were
different between groups or they were associated with PV. Scanner-site was used as a
covariate in each model tested.
The relationship between PV and sample characteristics (age, years of education, SES,
PSES, WAIS, MMSE, illness duration, symptom onset, chlorpromazine equivalence,
PANSS, SANS, SAPS, whole brain volume) were examined with Spearman’s and Pearsons
correlations as deemed appropriate. Post-hoc analyses were adjusted for multiple
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comparisons with Bonferroni correction. Two-tailed statistical significance level was set at
p<0.05. All analyses were conducted with the PASW Statistics software version 17.0
(Chicago, IL, USA: SPSS Inc.).
3 RESULTS
3.1 Sample characteristics
Sample sociodemographic and clinical characteristics of the SPD, FESZ, CHSZ, and HC
group are presented in Table 1. The FESZ were younger (p<0.05) and the CHSZ were older
(p<0.001) than the other groups, whereas the SPD and HC group were not different in mean
age (p=1.00). SPD and HC had more years of education than FESZ and CHSZ (p<0.05), but
there were no differences in years of education between SPD and HC or between FESZ and
CHSZ (p>0.05). CHSZ had lower (p=0.008), and FESZ had a trend (p=0.073) for lower
socioeconomic status (SES) compared to HC, whereas FESZ had higher parental
socioeconomic status (PSES) than all other groups (p<0.05). CHSZ had lower WAIS-III
verbal IQ scores than SPD and HC (p<0.01), but there were no differences between SPD and
HC (p=0.21). Further, CHSZ had lower WAIS-III vocabulary scaled scores than SPD and
HC (p<0.01), but not FESZ (p=0.11), and there were no differences between SPD, FESZ,
and HC (p>0.05). There were no significant differences between the groups in MMSE,
whole brain volume, symptom onset, chlorpromazine equivalence, PANSS, SAPS or SANS
scores.
All subjects from the SPD sample were antipsychotic naïve, whereas 13/15 FESZ
(typical=1, atypical=12) and 12/15 CHSZ (typical=3, atypical=9) were receiving
antipsychotic treatment. Information on medication status was unknown for 5 patients
(FESZ=2, and CHSZ=3).
3.2 Pituitary volume
Correlational analyses did not reveal a significant association between PV and any
sociodemographic, characteristic (p>0.05) or whole brain volume (r137= −0.002, p= 0.980),
except for years of education (r137= −0.217, p=0.011). Also, clinical subtests for symptom
severity, chlorpromazine equivalence, duration of illness, and age of symptom onset were
not associated with pituitary volume in FESZ or CHSZ, except for PANSS negative in
CHSZ (r15= −0.699, p=0.004). Women had significantly larger PV than men (ANCOVA
with whole brain volume as covariate: F= 4.99, df= 1, 134, p= 0.027).
In the first ANCOVA model, which included all study subjects (n=137), PV was the
dependent variable; group (i.e., SPD n=40, FESZ n=15, CHSZ n=15, HC n=67) and gender
(male n=99, female n=38) were the between-subject factors; and age, years of education,
SES, PSES, and whole brain volume were used as covariates. There was a main effect of
gender (F= 12.96, df= 1, 126, p<0.001; covariate-adjusted pituitary volume mean±SD,
female= 0.800±0.185, male= 0.656±0.189) (Figure 2a), but there was no group effect (F=
1.45, df= 3, 126, p= 0.232) or group by gender interaction (F= 2.28, df= 1, 126, p= 0.133).
The significant main effect of gender with a non-significant group by gender interaction
suggests that gender differences in pituitary volume are present in both SPD patients and
controls.
The second ANCOVA model (n=99) without female, but with male pituitary volume as
dependent variable, group (SPD n=20, FESZ n=15, CHSZ n=15, HC n=49) as between-
subject factor, and age, years of education, SES, PSES, and whole brain volume as
covariates revealed a significant main-effect for group (F= 3.38, df= 3, 90, p= 0.022). In
Bonferroni-corrected post-hoc analyses, male SPD had significantly smaller PV than male
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HC (p= 0.030) (Table 2, Figure 2b), but there were no group differences for the other pair-
wise comparisons (p>0.05).
The SPD group-effect was replicated in the third ANCOVA model (n=84) without female
and without CHSZ, but with male PV as dependent variable, group (SPD n=20, FESZ n=15,
HC n=49) as between-subject factor, and age, years of education, SES, PSES, and whole
brain volume as covariates (F= 5.21, df= 2, 76, p= 0.008). Male SPD had significantly
smaller PV than male HC (p= 0.007). ANCOVA model 3 was also further tested without
subjects from McLean hospital so that only subjects from Brigham and Women’s Hospital
were included in the analyses, thus effectively eliminating the potential confounding effects
of different scanners. In this additional analysis, the effects remained unchanged that is, we
found a main-effect for group (F= 3.38, df= 2, 61, p= 0.041) with significantly smaller PVs
for male SPD subjects compared to male controls (p=0.035).
Finally, to investigate further the SPD group effect and potential group by gender
interaction, we performed a fourth ANCOVA model (ICV, years of education; n=107)
directly comparing PV between the SPD group (n=40) and the healthy control group (n=67).
Results showed a main-effect for gender (F= 10.81, df= 1, 101, p= 0.001) indicating larger
PV for female subjects compared to male subjects. Furthermore, compared to controls, SPD
subjects had a trend for smaller PV (F= 2.83, df= 1, 101, p= 0.095), but no group by gender
interaction was observed (F= 1.78, df= 1, 101, p= 0.186), which suggests that the trend for
smaller PV observed in the SPD sample is independent from gender.
In all ANCOVA models, the main-effects remained the same with scanner-site as additional
covariate, and scanner-site was a non-significant independent predictor for PV volume in
each model.
4 DISCUSSION
In this study, we compared PV of subjects in the schizophrenia spectrum, which revealed
three main findings. First, male SPD subjects had smaller PV than male healthy control
subjects. No volumetric changes in FESZ or CHSZ were found. Second, there was a gender-
effect with women having larger volumes than men independent of group. Third, no effects
of medication dose in terms of chlorpromazine equivalents on PV were found for the FESZ
or CHSZ patients.
SPD shares clinical and neurobiological characteristics with schizophrenia (Raine, 2006),
and it has been documented that abnormalities in stress response and HPA axis functioning
are among the commonalities (Mitropoulou et al., 2004). It is thought that PV is influenced
by underlying HPA functioning, but evidence is scarce. Takahashi et al. (Takahashi et al.,
2009) were the first to report on PV in SPD (n=47, male=29), and found increased volumes
compared to healthy controls, which is opposite to our findings in the male SPD group
(n=20). Differences between the characteristics of the samples might help to explain this
discrepancy in results. Our result was found in male SPD subjects who were on average five
years older, neuroleptic naïve and recruited from the community, whereas the SPD group in
the Takahashi study was a clinical sample, and most of them received low dose anti-
psychotics and other medication. In a longitudinal study based on the same sample,
Takahashi found that volumes in SPD subjects increased during the follow up period
(mean=2.9yrs), and findings suggested that antipsychotics influence PV. (Takahashi et al.,
2011)
Our results of no volume difference between FESZ and HC contrasts with two recent studies
assessing PV in FE psychosis (Pariante et al., 2005; Pariante et al., 2004) where increased
PV in FESZ was reported. Mondelli (Mondelli et al., 2008) and Pariante (Pariante, 2008),
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have proposed that PV may change depending on stage of psychosis, i.e., during the
prodromal phase the PV increases (Garner et al., 2005), and after illness onset it tends to
become smaller. Interestingly, in the study performed by Upadhyaya et al (Upadhyaya et al.,
2007), PV in neuroleptic naïve SZ patients were significantly smaller than HC subjects.
Differences remained significant when gender was considered as a covariate, but when
comparing patients and controls by gender, there was no significant difference. In our study
no women were included in FESZ and HC group comparison.
We also found no difference in PV between CHSZ and HC groups. Previous studies
investigating PV in CHSZ have found smaller (Pariante et al., 2004; Upadhyaya et al., 2007)
and larger volumes (Pariante et al., 2005; Takahashi et al., 2009) compared to controls, but
our study did not replicate either of these findings. Our findings are consistent with those of
Tournikioti et al. (Tournikioti et al., 2007) who reported no differences between CHSZ and
controls in a sample comparable for age and gender to our sample. Our findings are also
consistent with those of Mondelli et al (Mondelli et al., 2008), but their schizophrenia
sample was seven years younger than our CHSZ group. Tournikioti et al. (Tournikioti et al.,
2007) postulated the possibility that age differences (10 yrs) between SZ and HC could help
explain the smaller pituitary volumes found in the SZ sample reported by Pariante (Pariante
et al., 2004).
Furthermore, the interpretation of findings in this and other studies is complicated by the
fact that patients often receive prolactin-increasing antipsychotics, which have been shown
to be related to changes in PV (MacMaster et al., 2007a). This notion about the
pharmacologic influence on PV has also been challenged with some of the studies reporting
no effect of medication on PV (Pariante et al., 2005; Pariante et al., 2004; Takahashi et al.,
2009; Tournikioti et al., 2007), suggesting that PV in the course of schizophrenia is
associated with several mediating factors, including antipsychotics, illness duration, and
illness stage. For example, in a recent one-year longitudinal study of a relatively young
chronic sample, Takahashi et al. (2012) reported that CHSZ patients treated with atypical
antipsychotics had significant pituitary reduction over time compared to those treated with
typical antipsychotics (Takahashi et al., 2012). Although most FESZ and CHSZ patients in
our sample received atypical antipsychotics, no effects of medication dose on PV were
found in either group.
We found significant gender differences in PV with females having larger volumes than
males regardless of diagnosis. Similar findings in PV have previously been reported
(Takahashi et al., 2009). However, MacMaster et al. (MacMaster et al., 2007b) examined the
effect of age and gender in a large sample of healthy controls (n=154, ages 7–35 years) and
found females to have larger volumes at younger ages (age group 14 to 17 years), but not at
older ages (age groups 18 through 35 years). In our sample, gender differences in both SPD
and HC groups were significant even though the mean age was 29 yrs. Takahashi et al.
(Takahashi et al., 2009) also found significant gender differences among SPD (mean age
male and female=25 yrs) and HC subjects (mean age male=25 yrs, female=24 yrs). In 1990,
Lurie et al. (Lurie et al., 1990) found no PV gender difference in healthy adults, but found a
negative correlation between PV and age (Lurie et al., 1990). The later consistent with
Doraiswamy (Doraiswamy et al., 1992) and Grams et al. (Grams et al.)
Overall, women had larger PV than men, and within the male sample all SSD subjects had
smaller PV than HC, statistically significant only for the SPD group. Discrepancies with
previous PV assessments in SSD suggest that the pituitary gland is a dynamic structure that
is sensitive to various sociodemographic variables, disease-related factors and biological
mechanisms. Additionally, atypical antipsychotics have consistently shown a down-
regulating effect on the proposed HPA hyperactivity in schizophrenia.(Bradley and Dinan,
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2010) Chronic, untreated HPA axis hyperactivity in SPD subjects could partially explain the
smaller PV finding, whereas treatment related acute and chronic HPA and neurotransmitter
modulation in FESZ and CHSZ patients might have a normalizing effect on PV in this two
groups. PV changes in SSD may be the result of a combined effect of the use of prolactin
elevating drugs increasing PV, and chronic elevated cortisol levels as a result of HPA axis
hyperactivity leading to decreased PV, as suggested by Pariante (Pariante et al., 2004). Other
studies have found that HPA axis dysfunction may be one of many vulnerability factors
shared by SSD. It is important to acknowledge that HPA axis activity is also regulated by
other systems (e.g., GABA, glutamate, dopamine), which at the same time might exert
volumetric changes by more direct pathways. For example, glutamatergic transmission has
been implicated as a critical regulator of the stress response (van den Pol et al., 1990). In
particular metabotropic glutamate receptors (mGluR) appear to play a crucial role in
mediating neuroendocrine responses to stress (Lang and Ajmal, 1995). Group II mGluR
agonists have shown to induce apoptosis in lactotropes indicating that the cytotoxic action of
glutamate is mainly exerted on this cell type through activation of group II mGluRs (Caruso
et al., 2004). Also, group II mGluR stimulation may increase the activity of tubero-
infundibular dopaminergic neurons by inhibiting the GABAergic input (Johnson and
Chamberlain, 2002). Dopamine exerts a tonic inhibitory effect on PRL release and reduces
the proliferation of lactotropes via D2 receptors (Sarkar et al., 2005), with a possible effect
on PV. This could help explain why a chronic, untreated HPA axis hyperactivity in
neuroleptic naive SPD subjects leads to a decreased pituitary volume, whereas treatment
related acute and chronic HPA and neurotransmitter modulation in FESZ and CHSZ patients
might have a normalizing effect on PV in these two groups. In other words, PV changes in
SSD may be the result of a combined effect of the use of prolactin elevating drugs (leading
to increased PV), and chronic elevated cortisol levels as a result of HPA axis hyperactivity
(leading to decreased PV), as suggested by Pariante (Pariante et al., 2004). These
mechanisms and others yet to be fully understood could contribute to the dynamic
volumetric changes and conflicting results that have been reported across studies
(MacMaster et al., 2007a; Mondelli et al., 2008; Pariante et al., 2004; Pariante et al., 2005;
Takahashi et al., 2009; Tournikioti et al., 2007; Upadhyaya et al., 2007).
Some limitations in this study have to be acknowledged. First, data has been gathered from
two different scanners. Although there is evidence supporting that volumetric variations
across different scanners is minimal (Jovicich et al., 2009), and we controlled for scanner-
site in the analyses, this should be considered as a possible source of bias in results. Second,
no endocrine measurements were made, and assumptions about the underlying substrate for
pituitary volumetric changes are made based on previous basic and clinical information
regarding HPA functioning and modulation by diverse neurotransmitter systems. It is
necessary to continue research with direct measurements of HPA axis products or
byproducts in order to confirm this hypothesis. Third, the FESZ and CHSZ group only
consisted of males. Examination of gender differences was thus not possible for these
groups. Lastly, even though we found no correlation between chlorpromazine equivalence
and PV, our sample did not include enough medication-free patients to fully determine the
potential confounding effects of medication.
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Figure 1.
The pituitary gland manually traced (colored; a, b) and 3-dimensionally reconstructed (c, d)
in sagital (a, c) and coronal (b, d) views.
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Figure 2.
Figure 2a–b. Pituitary volumes between genders (a) and across male groups (b) adjusted for
age, years of education, (parental) socioeconomic status, and whole brain volume. Data
points and horizontal bars represent group means; error bars represent 95% confidence
interval of the mean. Figure 2a: Women (n=38) have significantly larger pituitary volumes
than men (n=99) (p<0.001), but there is no group by gender interaction (p= 0.133), which
suggests that gender differences in pituitary volume are present in both SPD patients and
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controls. Figure 2b: The ANCOVA model (n=99) without females is significant for group
(p= 0.022). Male SPD have significantly smaller pituitary volume than male HC (p= 0.030)
in Bonferroni-corrected post-hoc analyses. There are no statistically significant group
differences for the other pair-wise comparisons (p>0.05). Abbreviations: SPD, schizotypal
personality disorder; FESZ, first-episode schizophrenia; CHSZ, chronic schizophrenia; HC,
healthy control subjects. *p<0.05, ***p<0.001.
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 st
at
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. A
ss
es
se
d 
us
in
g 
th
e 
H
ol
lin
gs
he
ad
 T
w
o-
Fa
ct
or
 m
ea
su
re
 (H
oll
ing
sh
ea
d, 
19
65
). C
HS
Z 
ha
d l
ow
er 
so
cio
ec
on
om
ic 
sta
tus
 th
an
 H
C 
(p=
0.0
08
). T
he
re 
wa
s a
tr
en
d 
di
ffe
re
nc
e 
be
tw
ee
n 
FE
SZ
 a
nd
 H
C 
(p=
0.0
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). T
he
re 
we
re 
no
 di
ffe
ren
ce
s f
or 
the
 ot
he
r g
rou
p c
om
pa
ris
on
s.
e F
ES
Z 
ha
d 
hi
gh
er
 p
ar
en
ta
l s
oc
io
ec
on
om
ic
 st
at
us
 th
an
 th
e 
ot
he
r g
ro
up
s (
p<
0.0
5).
f E
va
lu
at
ed
 u
sin
g 
th
e 
Ed
in
bu
rg
h 
H
an
de
dn
es
s I
nv
en
to
ry
 (O
ldf
iel
d, 
19
71
). V
alu
es 
> 0
 in
dic
ate
 ri
gh
t-h
an
de
dn
ess
. H
C 
ha
d s
tro
ng
er 
rig
ht 
ha
nd
 do
mi
na
nc
e t
ha
n S
PD
 (p
=0
.04
2).
g C
H
SZ
 h
ad
 lo
w
er
 W
A
IS
-II
I v
er
ba
l I
Q 
sco
res
 th
an
 SP
D 
an
d H
C 
(p<
0.0
1).
 T
he
re 
we
re 
no
 di
ffe
ren
ce
s b
etw
ee
n S
PD
 an
d H
C 
(p=
0.2
1).
h C
H
SZ
 h
ad
 lo
w
er
 W
A
IS
-II
I v
oc
ab
ul
ar
y 
sc
al
ed
 sc
or
es
 th
an
 S
PD
 a
nd
 H
C 
(p<
0.0
1),
 bu
t n
ot 
FE
SZ
 (p
=0
.11
). T
he
re 
we
re 
no
 di
ffe
ren
ce
s b
etw
ee
n S
PD
, F
ES
Z,
 an
d H
C 
(p>
0.0
5).
i D
eg
re
es
 o
f f
re
ed
om
 d
iff
er
 a
m
on
g 
va
ria
bl
es
 d
ue
 to
 u
na
va
ila
bi
lit
y 
of
 d
at
a 
fo
r s
om
e 
su
bje
cts
.
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Table 2
Male pituitary volumes across groups
SPD FESZ CHSZ HC
N 20 15 15 49
Pituitary gland, mL 0.621 (0.148)a 0.638 (0.164) 0.694 (0.173) 0.736 (0.151)
Values represent covariate-adjusted mean (SD). Abbreviations: SPD, schizotypal personality disorder; FESZ, first-episode schizophrenia; CHSZ,
chronic schizophrenia; HC, healthy control subjects.
ANCOVA followed by Bonferroni post-hoc t-tests were used. Age, years of education, (parental) socioeconomic status, and whole brain volume
were used as covariates for pituitary volume.
ap=0.030 compared to healthy controls (HC).
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